RY103
Phase 1- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Neuracle Genetics
Seoul, Seoul, South Koreareyonpharm.co.kr ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Neuracle Genetics is developing AAV-based gene therapy products, with programs currently in discovery phase. Their pipeline includes NG-201 for Alzheimer Disease and NG-101 for wet age-related macular degeneration.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- AAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Reyonpharm (for NG-101)
Beyond the preview
Go deeper on Neuracle Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuracle Genetics.